Mylan Gears To Make Otsuka’s MDR TB Drug In India
Executive Summary
Manufacturing plans for multidrug-resistant tuberculosis (MDR-TB) drug Deltyba (delamanid) in India appear to be gathering steam, with partners Otsuka and Mylan commencing the technology transfer process for the product, although activists are concerned about the broader contours of the arrangement. Deltyba is also expected to be used in children and adolescents in India.
You may also be interested in...
Big Pharma Advances Efforts In TB But Pricing Stays Key Concern
Price cuts, new treatments for TB and alliances to improve access to these medicines were among the key talking points at the recently concluded Union World Conference on Lung Health in India. TB survivors and activists were also vocal and pressed hard for their demands to be heard.
Call For India Compulsory Licenses For Last Resort TB Drugs
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?
Otsuka, which has been under fire over delayed access to delamanid in India, appears to have allied with Mylan, which has now secured a key clearance for the novel multidrug-resistant TB therapy in the country.